Creo Medical continues to make strong progress on both development and commercial fronts. Following its direct entry into the US, the company recently reported its first commercial revenues from that market, building upon the broad commercial reach developed via its signed-up distributor network. While lead product, Speedboat, is making commercial progress, Creo expects to launch a further four endoscopic instruments on the CROMA Advanced Energy platform during 2020, significantly expanding the ....
02 Dec 2019
Cenkos: Creo Medical Group Plc - Cutting edge
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Cenkos: Creo Medical Group Plc - Cutting edge
Creo Medical Group Plc (CREO:LON) | 34.5 0 0.0% | Mkt Cap: 124.7m
- Published:
02 Dec 2019 -
Author:
Chris Donnellan -
Pages:
32
Creo Medical continues to make strong progress on both development and commercial fronts. Following its direct entry into the US, the company recently reported its first commercial revenues from that market, building upon the broad commercial reach developed via its signed-up distributor network. While lead product, Speedboat, is making commercial progress, Creo expects to launch a further four endoscopic instruments on the CROMA Advanced Energy platform during 2020, significantly expanding the ....